Microbiome

Microbiome research company Clinical Microbiomics has acquired MS-Omics, a leading provider based in Denmark.   With this acquisition, Clinical Microbiomics hopes to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.    Anders Grøn, CEO at Clinical Microbiomics, commented: “There is an unmet need in the […]

Rebecca McClellan, Scientific Program Manager, Research, Development & Communications, explains how scientists are learning more about the connections between the microbiome and human health to potentially develop first-in-class microbiome therapies. Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive […]

Exploitation of microbiome science will unlock multiple commercial opportunities across a number of industries including life sciences. But there is a need for more effective data and process management to get the best from microbiome data, according to Dr Sven Sewitz, Director of Biodata Innovation at Eagle Genomics. The microbiome comprises trillions of diverse bacteria […]

Genetic Analysis has announced a Service Agreement with Eurofins ADME Bioanalysis, a CRO who have launched a standardised gut microbiome test (GA-map Dysbiosis Test).  Gut microbiome profiling is required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due to both the impact new pharmaceuticals can have on microbiomes and the fact that the […]

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release to reconfigure bioprocessing and cell-based assays”, where the authors Dr […]

Microbiome experts from Microba Life Sciences will discuss the next phase of discovery from the microbiome to a global audience via a series of webinars on September 15 (PST 10am-12pm | EST 1-3pm | CET 7pm).  Professor Gene Tyson, Associate Professor Lutz Krause and Dr Alena Pribyl will discuss how advancements in metagenomic analysis techniques are revealing novel biomarkers and relationships […]

CN Bio has licenced a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University to investigate the direct interaction between the microbiome and gut and the wider effects of the microbiome on organs such as the liver and brain. Planned for commercial launch in 2023, the technology […]

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is a space with high potential, […]

King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver model with a range of […]

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an easy to use, in vitro […]